Number of items: 2.
2022
Einerhand, Sarah M. H.,
Black, Anna J.,
Zargar, Homayoun ,
Fairey, Adrian S.,
Dinney, Colin P.,
Mir, Maria C.,
Krabbe, Laura-Maria,
Cookson, Michael S.,
Jacobson, Niels-Erik,
Montgomery, Jeffrey S.,
Vasdev, Nikhil ,
Yu, Evan Y.,
Xylinas, Evanguelos,
Kassouf, Wassim,
Dall’Era, Marc A.,
Sridhar, Srikala S.,
McGrath, Jonathan S.,
Aning, Jonathan,
Shariat, Shahrokh F.,
Wright, Jonathan L.,
Thorpe, Andrew C.,
Morgan, Todd M. ,
Holzbeierlein, Jeff M.,
Bivalacqua, Trinity J.,
North, Scott,
Barocas, Daniel A.,
Lotan, Yair,
Grivas, Petros,
Garcia, Jorge A.,
Stephenson, Andrew J.,
Shah, Jay B.,
Daneshmand, Siamak,
Zargar-Shoshtari, Kamran,
Spiess, Philippe E.,
van Rhijn, Bas W. G.,
Black, Peter C. and
Mertens, Laura S.
(2022)
Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer.
World Journal of Urology 40 (11), pp. 2707-2715.
Fulltext not available.
Pal, Sumanta K.,
Somford, Diederik M.,
Grivas, Petros,
Sridhar, Srikala S.,
Gupta, Shilpa,
Bellmunt, Joaquim,
Sonpavde, Guru,
Fleming, Mark T.,
Lerner, Seth P.,
Loriot, Yohann,
Hoffman-Censits, Jean,
Valderrama, Begoña P.,
Andresen, Corina,
Schnabel, Marco J.,
Cole, Suzanne and
Daneshmand, Siamak
(2022)
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.
Future Oncology 18 (21), pp. 2599-2614.
Fulltext not available.
This list was generated on Mon Dec 9 11:21:21 2024 CET.